Cancer Therapy

Efficacy and safety for cancer immunotherapy preclinical results published

Published in Vaccine Weekly, October 20th, 2004

Cerus Corporation (Nasdaq:CERS) announced the publication of preclinical efficacy and safety data for its cancer immunotherapy technology in the the Proceedings of the National Academy of Sciences (PNAS).

Together with two papers validating cancer antigens published by independent groups, Cerus now has mounting evidence supporting the intensified development of its cancer immunotherapy technology. The most recent paper describes studies in which experimental vaccines based on a proprietary attenuated listeria strain were engineered to express tumor antigens.

These vaccines were shown to elicit therapeutic antitumor responses, including...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-10-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry